Anti-TAK1 antibody
Specifications
| Product Cat#: | AB-06-4271 |
| Product type: | Primary antibody |
| Antigen: | TAK1 |
| Immunogen: | Synthetic peptide within Human TAK1 aa 560 to the C-terminus . |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Immunohistochemistry (1:100-1:200); Flow Cytometry (1:50-1:200); Immunocytochemistry (1:100-1:200) |
| Reactivity: | Human, Mouse, Rat |
| Clonality (clone number): | Polyclonal |
| Form: | Liquid |
| Buffer: | 1*TBS (pH 7.4), 0.5% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide. |
| Concentration: | 1 mg/ml |
| Purity: | Peptide affinity purified. |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | M3K7_HUMAN antibody |
| MAP3K 7 antibody | |
| Map3k7 antibody | |
| MEKK7 antibody | |
| Mitogen activated protein kinase kinase kinase 7 antibody | |
| Mitogen-activated protein kinase kinase kinase 7 antibody | |
| TAK1 antibody | |
| TGF beta activated kinase 1 antibody | |
| TGF-beta-activated kinase 1 antibody | |
| TGF1a antibody | |
| Transforming growth factor beta activated kinase 1 antibody | |
| Transforming growth factor-beta-activated kinase 1 antibody |
Target information
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR). Ceramides are also able to activate MAP3K7/TAK1. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs, c-jun N-terminal kinases (JNKs) and I-kappa-B kinase complex (IKK). Both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1), while nuclear factor-kappa B is activated by IKK. MAP3K7 activates also IKBKB and MAPK8/JNK1 in response to TRAF6 signaling and mediates BMP2-induced apoptosis. In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B. Promotes TRIM5 capsid-specific restriction activity.
Provider
Erpantech Laboratory
